增加铋剂和抗生素剂量未提高幽门螺杆菌根除效果:Hp-EuReg登记研究
基于Hp-EuReg国际前瞻性登记研究,分析2013至2024年含铋四联方案按剂量分层的疗效。共纳入10,767例初治和2,952例补救治疗,mITT分析显示超过标准剂量并未提升根除率,初治方案在标准剂量下可达90%左右,补救治疗均低于90%。
要点
- 初治CAB方案在阿莫西林2000mg/d和克拉霉素1000mg/d标准剂量下疗效>90%,与铋剂剂量无关。
- 补救治疗各含铋四联方案mITT均<90%,增加铋剂剂量无显著差异。
- 依从性、疗程和PPI联合治疗可能比增加抗生素/铋剂剂量更重要。
核心结论
- 超过标准剂量增加抗生素或铋剂并未改善幽门螺杆菌根除效果。
研究设计与样本
- 国际前瞻性非干预性登记研究(Hp-EuReg),纳入2013至2024年接受经验性含铋四联治疗的患者,采用改良意向性分析(mITT)评估疗效。
主要发现
- 初治CAB方案在阿莫西林2000mg/d和克拉霉素1000mg/d标准剂量下疗效>90%,与铋剂剂量无关。
- 初治BMTc方案在四环素≥1500mg/d、甲硝唑1500mg/d和铋剂≥480mg/d时疗效>90%。
- 初治AMB方案在阿莫西林2000mg/d、甲硝唑≥1000mg/d和铋剂480mg/d时mITT约90%。
- 初治CMB方案在甲硝唑≥800mg/d时mITT≥90%,增加铋剂剂量无改善。
- 补救治疗(2-6线)共2952例,所有方案mITT<90%(ALB 83%、BMTc 79%、CAB 88%、MDB 63%、AMB 88%),不同铋剂剂量无显著差异。
关键数值与推荐
- 初治CAB:阿莫西林2000mg/d、克拉霉素1000mg/d,疗效>90%,铋剂剂量不限。
- 初治BMTc:四环素≥1500mg/d、甲硝唑1500mg/d、铋剂≥480mg/d,疗效>90%。
- 初治AMB:阿莫西林2000mg/d、甲硝唑≥1000mg/d、铋剂480mg/d,mITT约90%。
- 初治CMB:甲硝唑≥800mg/d时mITT≥90%,增加铋剂无改善。
- 补救治疗各方案mITT均<90%,增加铋剂剂量无显著差异。
临床怎么用
- 初治含铋四联方案应采用标准剂量抗生素和铋剂,无需超量。
- 补救治疗疗效有限,应关注依从性、疗程和PPI联合治疗而非增加剂量。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Evidence on optimal bismuth and antibiotic dosing is limited. We aimed to analyze the effectiveness of bismuth-containing quadruple regimens according to drug dosage. METHODS: This was an analysis of an international, prospective, non-interventional registry on the management of Helicobacter pylori infection by European gastroenterologists (European Registry on Helicobacter pylori Management [Hp-EuReg]). Patients receiving empirical bismuth-containing quadruple therapies in any treatment line and registered from 2013 to 2024 were included. Effectiveness was assessed using a modified intention-to-treat (mITT) analysis. RESULTS: A total of 10,767 first-line records were analyzed. The clarithromycin-amoxicillin-bismuth (CAB) scheme was >90% effective with standard doses of amoxicillin and clarithromycin (2000 mg/d and 1000 mg/d), regardless of bismuth dose. The bismuth-metronidazole-tetracycline (BMTc) regimen achieved >90% effectiveness with tetracycline ≥1500 mg/d, metronidazole 1500 mg/d, and bismuth ≥480 mg/d. The amoxicillin-metronidazole-bismuth (AMB) regimen reported ≈90% mITT with amoxicillin 2000 mg/d, metronidazole ≥1000 mg/d, and bismuth 480 mg/d. The clarithromycin-metronidazole-bismuth (CMB) showed ≥90% mITT with metronidazole ≥800 mg/d, without improvement from increasing bismuth dose. In the amoxicillin-levofloxacin-bismuth (ALB) regimen, mITT was >90%, with no benefit from increasing levofloxacin >500 mg/d. A total of 2952 second- to sixth-line treatments were analyzed, all showing mITT <90% (ALB, 83%; BMTc, 79%; CAB, 88%; MDB, 63%; AMB, 88%), with no significant differences with different bismuth doses. CONCLUSIONS: Increasing antibiotic or bismuth doses above the standard did not improve effectiveness of H pylori treatment. Adherence, treatment length, and proton pump inhibitor co-therapy may be more impactful than escalation of antibiotics/bismuth doses. CLINICALTRIALS: gov, Number: NCT02328131.
引用
- Martínez-Domínguez SJ, Lanas Á, Ceamanos E, et al. Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management. Clin Gastroenterol Hepatol. 2026. PMID: 41935593. doi:10.1016/j.cgh.2026.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。